{"id":"W4391614640","doi":"10.1007/s10637-023-01410-2","title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Randomized controlled trial; Pembrolizumab; Medicine; Antagonist; Internal medicine; Cancer; Immunotherapy; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001515112,0.001496121,0.001845241,0.0004011761,0.000374035,0.0009048561,0.0007395254,0.001276039,0.004554959],"category_scores_gemma":[0.0008833606,0.0005541429,0.001104232,0.0003784125,0.0007834567,0.0007979247,0.0002852644,0.002161647,0.0007676416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008044285,"about_ca_system_score_gemma":0.001141983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008916541,"about_ca_topic_score_gemma":0.002466495,"domain_scores_codex":[0.9996203,0.0002058475,0.00001801231,0.00005846156,0.00003082024,0.00006650363],"domain_scores_gemma":[0.9996044,0.00007954732,0.00009471737,0.00002999513,0.00002764952,0.000163649],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9299379,0.01582317,0.001353342,0.000713977,0.0009353202,0.0001267051,0.0001146659,0.0009648429,0.008732216,0.0003195885,0.002862688,0.03811559],"study_design_scores_gemma":[0.9208757,0.07466237,0.00161378,0.00003165621,0.0002197044,0.00007229923,0.0000187959,0.0007665445,0.0004959474,0.000147006,0.00108544,0.00001088162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869722,0.003690443,0.0006683516,0.0008827922,0.0002763286,0.003914555,0.001054473,0.0001494874,0.002391362],"genre_scores_gemma":[0.981047,0.003483703,0.002121547,0.001462278,0.0004313927,0.006130613,0.001725716,0.00003028941,0.003567461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004554959,"threshold_uncertainty_score":0.01523787,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01262812956067111,"score_gpt":0.3092178169209199,"score_spread":0.2965896873602488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}